<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cortisone acetate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cortisone acetate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cortisone acetate: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12341" href="/d/html/12341.html" rel="external">see "Cortisone acetate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13182" href="/d/html/13182.html" rel="external">see "Cortisone acetate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F154760"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Systemic</li></ul></div>
<div class="block doa drugH1Div" id="F154730"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize dosing depending upon the severity of the disease and clinical response. Once a satisfactory response is achieved, reduce dosage to the lowest possible dose for maintenance. Temporary supplemental doses may be warranted during times of stress (ie, trauma, surgery, severe infection). Discontinuation of therapy requires gradual withdrawal by tapering the dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="887c00ba-1eff-432f-a8c3-5bbbb8805034">Adrenal insufficiency, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, chronic (eg, primary, secondary): Oral: </b>20 to 35 mg/day in 2 to 3 divided doses. Administer the largest dose in the morning upon awakening, followed by next dose 2 hours after lunch (2-dose regimen) <b>or</b> next dose at lunch, followed by smallest dose in the afternoon no later than 4 to 6 hours before bedtime (3-dose regimen) (ES [Bornstein 2016]; ES [Fleseriu 2016]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a6608b3-fd67-4c09-a374-bc417c0679c2">Anti-inflammatory or immunosuppressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory or immunosuppressive:</b>
<b>Oral:</b> Initial: 25 to 300 mg/day; adjust dose to patient response.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990916"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988195"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F154731"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F154747"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13182" href="/d/html/13182.html" rel="external">see "Cortisone acetate: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dose depends upon condition being treated and response of patient; dosage for children and adolescents should be based on disease severity and patient response rather than by rigid adherence to dosage guidelines by age, weight, or body surface area. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a6608b3-fd67-4c09-a374-bc417c0679c2">Anti-inflammatory or immunosuppressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory or immunosuppressive:</b> Children and Adolescents: Oral: General range: 0.7 to 10 mg/kg/day; or 20 to 300 mg/m<sup>2</sup>/day in divided doses every 6 to 8 hours; usual range: 2.5 to 10 mg/kg/day (Nelson 1996; Rudolph 1996); usual adult daily dose range: 25 to 300 mg/<b>day</b> (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e58012da-026c-41dd-80fe-2f3b7e31cf6d">Congenital adrenal hyperplasia, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia, maintenance: Note:</b> Other corticosteroids (eg, hydrocortisone) are preferred over cortisone. Mineralocorticoid (eg, fludrocortisone) and sodium supplementation may be required in salt losers (AAP 2000; ES [Bornstein 2016]; ES [Speiser 2018]; Inada 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Limited data available, variable regimens reported: Oral: 10 to 25 mg/m<sup>2</sup>/day in 3 divided doses; reported range: 10 to 36 mg/m<sup>2</sup>/day in divided doses. Individualize dose based on growth, bone age, and hormone levels (AAP 2000; Einaudi 1993; ES [Speiser 2018]; Gomes 2013; Keenan 1990; Moreira 2011). Usual adult daily dose range: 20 to 35 mg/<b>day</b> (ES [Bornstein 2016]). Some experts recommend administering the highest dose first thing in the morning, and lower doses for the last 2 doses to attempt to mimic the normal diurnal variation of endogenous cortisol (ES [Bornstein 2016]; Shulman 2007).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090022"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51090023"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F154704"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (in susceptible patients), myocardial rupture (after recent myocardial infarction), thromboembolism</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, diaphoresis, ecchymoses, erythema of skin, skin atrophy, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium, fluid retention, hirsutism, hypokalemic alkalosis, menstrual disease, negative nitrogen balance (due to protein catabolism), sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Impaired intestinal carbohydrate absorption, increased appetite, intestinal perforation, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Petechia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, increased intracranial pressure (with papilledema), malaise, psychosis, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Amyotrophy, aseptic necrosis of femoral head, aseptic necrosis of humeral head, pathological fracture (long bone), rupture of tendon, steroid myopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Exophthalmos</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (van der Hooft 2006), hypertension (Mebrahtu 2020), venous thrombosis (Johannesdottir 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal suppression (Broersen 2015), Cushing syndrome (Hopkins 2005), cushingoid appearance (Hopkins 2005), diabetes mellitus (including exacerbation of diabetes mellitus) (Tamez-Perez 2015), dyslipidemia (Vodnala 2012), growth retardation (children) (Liu 2013), hyperglycemia (Tamez-Perez 2015), moon face (Hopkins 2005), prediabetes (Tamez-Perez 2015), redistribution of body fat (Hopkins 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (Liu 2013), pancreatitis (Liu 2013), peptic ulcer (with possible perforation and hemorrhage) (Liu 2013), ulcerative esophagitis (Liu 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychiatric disturbance (including agitation, anxiety, distractibility, euphoria, fear, hypomania, irritability, labile mood, lethargy, pressured speech, restlessness, tearfulness) (Ciriaco 2013; Warrington 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteoporosis (Buckley 2018), vertebral compression fractures (Buckley 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma (Razeghinejed 2012), subcapsular posterior cataract (Urban 1986)</p></div>
<div class="block coi drugH1Div" id="F154716"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cortisone or any component of the formulation; systemic fungal infection; administration of live virus vaccines (with immunosuppressive doses of cortisone).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): The Canadian product monograph describes various conditions as relative contraindications, including but not limited to, infections (fungal, mycobacterial, viral), ocular herpes simplex, acute psychoses, diverticulitis, and pregnancy; refer to the product monograph for further details.</p></div>
<div class="block war drugH1Div" id="F154701"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with tuberculosis (TB) infection (latent TB) and/or TB reactivity; restrict use in TB disease (active TB) (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropical climates or unexplained diarrhea prior to initiation of corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including severe depression, euphoria, insomnia, mood swings, personality changes, to frank psychotic manifestations. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure and/or hypertension; use has been associated with electrolyte disturbances, fluid retention, and hypertension. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis [nonspecific) due to perforation risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use. Monitor BP and renal function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May affect growth velocity; growth and development should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878400"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard 2007). Increased intraocular pressure (IOP) may occur, especially with prolonged use. In children, increased IOP has been shown to be dose and age dependent; children 3 to &lt;6 years of age treated with ophthalmic dexamethasone experienced higher peak IOP as compared to children 6 to 10 years (Lam 2005).</p></div>
<div class="block foc drugH1Div" id="F154710"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block geq drugH1Div" id="F154697"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524430"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cortisone Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $18.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866449"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block adm drugH1Div" id="F154713"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with food to decrease GI upset.</p></div>
<div class="block admp drugH1Div" id="F52612458"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals, food, or milk to decrease GI effects.</p></div>
<div class="block use drugH1Div" id="F154711"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic states:</b> Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment of atopic dermatitis, bronchial asthma, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, and serum sickness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatologic diseases:</b> Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), severe psoriasis, severe seborrheic dermatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocrine disorders:</b> Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis, primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids when applicable; in infancy, mineralocorticoid supplementation is of particular importance).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>GI diseases:</b> During acute episodes of regional enteritis and ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic disorders:</b> Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia, erythroblastopenia (red blood cell [RBC] anemia), immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) in adults, secondary thrombocytopenia in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neoplastic diseases:</b> Palliative management of leukemias and lymphomas in adults; acute leukemia of childhood.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic diseases:</b> Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa (eg, allergic conjunctivitis, allergic corneal marginal ulcers, anterior segment inflammation, chorioretinitis, diffuse posterior uveitis and choroiditis, keratitis, herpes zoster ophthalmicus, iritis and iridocyclitis, optic neuritis, sympathetic ophthalmia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal diseases:</b> To induce diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that is caused by systemic lupus erythematosus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory diseases:</b> Aspiration pneumonitis, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy, Loeffler syndrome not manageable by other means, symptomatic sarcoidosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatic disorders:</b> Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute and subacute bursitis; acute gouty arthritis; acute nonspecific tenosynovitis; ankylosing spondylitis; epicondylitis; posttraumatic osteoarthritis; psoriatic arthritis; rheumatoid arthritis (RA), including juvenile RA (select cases may require low-dose maintenance therapy); and synovitis of osteoarthritis. During an exacerbation or as maintenance therapy in select cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), and systemic lupus erythematosus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Miscellaneous:</b> Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.</p></div>
<div class="block mst drugH1Div" id="F154767"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cortisone may be confused with Cardizem, Cortizone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299096"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F154706"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Cortisone may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Cortisone may diminish the diagnostic effect of Cosyntropin.  Management: Patients receiving cortisone should omit their pre-test dose on the day selected for cosyntropin testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Cortisone may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Cortisone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Cortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tesamorelin: May decrease serum concentrations of the active metabolite(s) of Cortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F6472607"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cortisone crosses the placenta (Migeon 1957).</p>
<p style="text-indent:0em;margin-top:2em;">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; however, information is conflicting and may be influenced by maternal dose, duration/frequency of exposure, and indication for use. Additional data is needed to evaluate any potential risk of systemic corticosteroids and other adverse pregnancy outcomes (eg, gestational diabetes mellitus, low birth weight, preeclampsia, preterm birth) (ACOG 2019; Bandoli 2017; Lunghi 2010; Skuladottir 2014). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>
<p style="text-indent:0em;margin-top:2em;">Cortisone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) during pregnancy. Pregnant patients with PAI should be monitored at least once each trimester (ES [Bornstein 2016]).</p></div>
<div class="block brc drugH1Div" id="F21279059"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interference with endogenous corticosteroid production).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer in patients taking pharmacologic doses. If there is concern about exposure to the infant, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfeeding infant (based on a study using prednisolone) (Butler 2014; Ost 1985).</p></div>
<div class="block dic drugH1Div" id="F154717"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May need diet with increased potassium, pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus and decreased sodium; may be taken with food to decrease GI upset.</p></div>
<div class="block mop drugH1Div" id="F45497377"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum glucose, electrolytes, BP, weight, presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); signs and symptoms of behavioral or mood changes; signs and symptoms of Cushing syndrome every 6 months; eye exams (with prolonged use).</p></div>
<div class="block pha drugH1Div" id="F154700"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability</p></div>
<div class="block phk drugH1Div" id="F154715"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Readily</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Distributes to muscles, liver, skin, intestines, and kidneys </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to active metabolite hydrocortisone (cortisol)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Interindividual variability: 43.7% (reported range: 20% to 95%) (Heazelwood 1984)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~0.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: ~2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and feces (Czock 2005)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038589"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cortone azetat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cortate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adreson | Cortisone pfizer</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cortison Ciba</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cortisone</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cortison Ciba</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cortison</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cortone</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cortisone roussel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cortelan | Cortistab | Cortisyl</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cortone</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cortate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adreson</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cortisyl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cortone acetato</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cortisyl</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cortone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cortisoni acetas</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Adreson</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cortison | Cortisoni acetas</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cortate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cortisonacet | Cortisonacetaat | Cortisonacetaat PCH</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cortison | Cortison nycomed | Cortisonacetat | Cortone | Cortone acetato</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cortate | Cortisone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cortisone</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cortisone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cortal | Cortone</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cortisone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cortisoni acetas</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cortogen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11099616">
<a name="11099616"></a>American Academy of Pediatrics (AAP). Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. <i>Pediatrics</i>. 2000;106(6):1511-1518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/11099616/pubmed" id="11099616" target="_blank">11099616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 776: Immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol</i>. 2019;133(4):e287-e295. doi:10.1097/AOG.0000000000003176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28711148">
<a name="28711148"></a>Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. <i>Rheum Dis Clin North Am</i>. 2017;43(3):489-502. doi:10.1016/j.rdc.2017.04.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/28711148/pubmed" id="28711148" target="_blank">28711148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25844620">
<a name="25844620"></a>Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2015;100(6):2171-2180. doi:10.1210/jc.2015-1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/25844620/pubmed" id="25844620" target="_blank">25844620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586507">
<a name="30586507"></a>Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. <i>N Engl J Med</i>. 2018;379(26):2547-2556. doi:10.1056/NEJMcp1800214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/30586507/pubmed" id="30586507" target="_blank">30586507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-e10; quiz 427. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24347992">
<a name="24347992"></a>Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. <i>J Pharmacol Pharmacother</i>. 2013;4(Suppl 1):S94-S98. doi:10.4103/0976-500X.120975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/24347992/pubmed" id="24347992" target="_blank">24347992</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cortisone Acetate. <i>Martindale: The Complete Drug Reference</i>. Facts &amp; Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health Inc; 2011. Accessed November 1, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cortisone.1">
<a name="Cortisone.1"></a>Cortisone acetate tablets, USP [prescribing information]. Congers, NY: Chartwell RX LLC; January 2023.</div>
</li>
<li>
<div class="reference">
                  Cortisone acetate [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15634032">
<a name="15634032"></a>Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/15634032/pubmed" id="15634032" target="_blank">15634032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8348221">
<a name="8348221"></a>Einaudi S, Lala R, Corrias A, Matarazzo P, Pagliardini S, de Sanctis C. Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>J Pediatr Endocrinol</i>. 1993;6(2):173-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/8348221/pubmed" id="8348221" target="_blank">8348221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin</i>
<i>Endocrinol</i>
<i>Metab</i>. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23525308">
<a name="23525308"></a>Gomes LG, Madureira G, Mendonca BB, Bachega TA. Mineralocorticoid replacement during infancy for salt wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Clinics (Sao Paulo)</i>. 2013;68(2):147-152. doi:10.6061/clinics/2013(02)oa05<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/23525308/pubmed" id="23525308" target="_blank">23525308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6691888">
<a name="6691888"></a>Heazelwood VJ, Galligan JP, Cannell GR, et al. Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. <i>Br J Clin Pharmacol</i>. 1984;17(1):55-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/6691888/pubmed" id="6691888" target="_blank">6691888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15850848">
<a name="15850848"></a>Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. <i>Endocrinol Metab Clin North Am</i>. 2005;34(2):371-384,ix. doi:10.1016/j.ecl.2005.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/15850848/pubmed" id="15850848" target="_blank">15850848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24790292">
<a name="24790292"></a>Inada H, Imamura T, Nakajima R, Yamano T. Poor response to substitution therapy with cortisone acetate in patients with congenital adrenal hyperplasia. <i>Clin Pediatr Endocrinol</i>. 2004;13(1):11-15. doi:10.1297/cpe.13.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/24790292/pubmed" id="24790292" target="_blank">24790292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23546607">
<a name="23546607"></a>Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. <i>JAMA Intern Med</i>. 2013;173(9):743-752. doi:10.1001/jamainternmed.2013.122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/23546607/pubmed" id="23546607" target="_blank">23546607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2153199">
<a name="2153199"></a>Keenan BS, Eberle AE, Lin TH, Clayton GW. Inappropriate adrenal androgen secretion with once-a-day corticosteroid therapy for congenital adrenal hyperplasia. <i>J Pediatr.</i> 1990;116(1):133-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/2153199/pubmed" id="2153199" target="_blank">2153199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, et al, "Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial," <i>Clin Experiment Ophthalmol</i>, 2005, 33(3):252-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332238">
<a name="17332238"></a>Leonard MB, "Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease," <i>Pediatrics</i>, 2007, 119 Suppl 2:S166-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/17332238/pubmed" id="17332238" target="_blank">17332238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23947590">
<a name="23947590"></a>Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2013;9(1):30. doi:10.1186/1710-1492-9-30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/23947590/pubmed" id="23947590" target="_blank">23947590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al. Use of glucocorticoids in pregnancy.<i> Curr Pharm Des</i>. 2010;16(32):3616-3637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18504331">
<a name="18504331"></a>McGee S and Hirschmann J, “Use of Corticosteroids in Treating Infectious Diseases,” <i>Arch Intern Med</i>, 2008, 168(10):1034-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/18504331/pubmed" id="18504331" target="_blank">18504331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32392512">
<a name="32392512"></a>Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. <i>CMAJ</i>. 2020;192(12):E295-E301. doi:10.1503/cmaj.191012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/32392512/pubmed" id="32392512" target="_blank">32392512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13463100">
<a name="13463100"></a>Migeon CJ, Bertrand J, and Wall PE, "Physiological Disposition of 4-C14-Cortisol During Late Pregnancy," <i>J Clin Invest</i>, 1957, 36(9):1350-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/13463100/pubmed" id="13463100" target="_blank">13463100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21915484">
<a name="21915484"></a>Moreira RP, Jorge AA, Gomes LG, et al. Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Clinics (Sao Paulo)</i>. 2011;66(8):1361-1366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/21915484/pubmed" id="21915484" target="_blank">21915484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998938">
<a name="3998938"></a>Ost L, Wettrell G, Bjorkhem I, et al, "Prednisolone Excretion in Human Milk," <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/3998938/pubmed" id="3998938" target="_blank">3998938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757964">
<a name="21757964"></a>Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. <i>Ophthalmic Res</i>. 2012;47(2):66-80. doi:10.1159/000328630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/21757964/pubmed" id="21757964" target="_blank">21757964</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rudolph AM, Hoffman JIE, Rudloph, CD, eds. <i>Rudolph's Pediatrics</i>. 20th ed. Stamford, CT: Appleton &amp; Lange; 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242136">
<a name="17242136"></a>Shulman DI, Palmert MR, Kemp SF, Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. <i>Pediatrics</i>. 2007;119(2):e484-494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/17242136/pubmed" id="17242136" target="_blank">17242136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777675">
<a name="24777675"></a>Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. <i>Birth Defects Res A Clin Mol Teratol</i>. 2014;100(6):499-506. doi:10.1002/bdra.23248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/24777675/pubmed" id="24777675" target="_blank">24777675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi: 10.1210/jc.2018-01865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240704">
<a name="26240704"></a>Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. <i>World J Diabetes</i>. 2015;6(8):1073-1081. doi:10.4239/wjd.v6.i8.1073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/26240704/pubmed" id="26240704" target="_blank">26240704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3541262">
<a name="3541262"></a>Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. <i>Surv Ophthalmol</i>. 1986;31(2):102-110. doi:10.1016/0039-6257(86)90077-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/3541262/pubmed" id="3541262" target="_blank">3541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16682576">
<a name="16682576"></a>van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. <i>Arch Intern Med</i>. 2006;166(9):1016-1020. doi:10.1001/archinte.166.9.1016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/16682576/pubmed" id="16682576" target="_blank">16682576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22658245">
<a name="22658245"></a>Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. <i>Am J Cardiol</i>. 2012;110(6):823-825. doi:10.1016/j.amjcard.2012.04.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/22658245/pubmed" id="22658245" target="_blank">22658245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17036562">
<a name="17036562"></a>Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. <i>Mayo Clin Proc</i>. 2006;81(10):1361-1367. doi:10.4065/81.10.1361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cortisone-acetate-drug-information/abstract-text/17036562/pubmed" id="17036562" target="_blank">17036562</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9297 Version 279.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
